

SEED

Intellectual Property Law Group PLLC

9200
701 Fifth Avenue, Suite 6300
Seattle WA 98104-7092 USA
Facsimile: (206) 682-6031
Telephone: (206) 622-4900
www.seedlaw.comJulie A. Urvater, Ph.D.
julieu@seedlaw.com

January 24, 2003

Facsimile Transmission5 pages including this page**TO: Examiner Ronald B. Schwadron**

Fax No.: 703-308-4242

Phone No.: 703-308-4680

FAX RECEIVED

JAN 27 2003

RE: Office Communication (Supply Omission/Correction of 4/1/02)

Your Reference: 09/164,223

GROUP 1600**Our Reference: 210121.465****OFFICIAL**☐ Urgent ☐ For Review ☐ Please Confirm Receipt ☐ Please Reply ASAP**Comments:**

Dear Examiner Schwadron:

Attached are the following with regard to Office Letter mailed on April 1, 2002:

1. Official Communication Letter of January 24, 2003;
2. Copy of fax transmission of April 9, 2002 responding to Office letter mailed on April 1, 2002;
3. Copy of confirmation of fax transmission of April 9, 2002 responding to Office letter mailed on April 1, 2002.

If you do not receive all pages, please call Judith Davies at (206) 622-4900 or fax our office.

Transmission Information: Date _____ Time _____ By _____

CONFIDENTIALITY NOTICE: The information contained in this facsimile message is legally privileged and/or confidential information intended only for the use of the addressee named above. If you are not the intended recipient, you are hereby notified that any use, dissemination, distribution, or copying of this facsimile or its content is strictly prohibited. If you have received this facsimile in error, please immediately notify us by telephone and return the original facsimile message to us by mail or destroy it without making a copy. Thank you.

SEED**Intellectual Property Law Group PLLC**

701 Fifth Avenue, Suite 6300
Seattle, WA 98104-7092 USA
Telephone: (206) 622-4900
Facsimile: (206) 682-6031
www.seedlaw.com

January 24, 2003

Julie A. Urvater, Ph.D.
julieu@seedlaw.com

By Facsimile (703) 308-4242**OFFICIAL COMMUNICATION**

Examiner Ronald B. Schwadron
Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application 09/164,223 entitled
COMPOSITIONS AND METHODS FOR WT1 SPECIFIC IMMUNOTHERAPY
Our Reference: 210121.465

Dear Examiner Schwadron:

We received a Notice of Abandonment, mailed on January 13, 2003, for the above-identified application. The Notice was issued in view of Applicant's alleged failure to timely file a proper reply to your communication to supply an omission, mailed on April 1, 2002. In the communication of April 1, 2002, you indicated that the marked-up version of the claims did not reflect the deletion of "or 3" in claim 110.


As per my notes, I spoke with you on April 8, 2002 regarding the inadvertent omission and you requested that I fax to you a copy of the corrected version of the claims with markings to show changes made. Attached hereto are the facsimile cover sheet, the corrected version of the claims with markings to show changes made that were faxed to you on April 9, 2002, and the confirmation that the fax transmission was completed.

In light of the above, it appears that a reply to the request for omission was indeed filed in a timely fashion and that the Notice of Abandonment was issued erroneously. A reinstatement of the instant application is respectfully requested.

I will contact you by telephone on Monday, January 27, 2003 to confirm receipt of this letter and to discuss any remaining issues you may have regarding reinstatement of the application.

Very truly yours,

SEED Intellectual Property Law Group PLLC


Julie A. Urvater, Ph.D.

Enclosures: As Noted

C:\Nrporth\l\Managc\JULIEU\351709_1.DOC

SEED

Intellectual Property Law Group PLLC

101 Fifth Avenue, Suite 6300
Seattle WA 98104-7092 USA
Facsimile: (206) 682-6031
Telephone: (206) 622-4900
www.seedlaw.com

Julie A. Urvater, Ph.D.
julieu@seedlaw.com

April 9, 2002

Facsimile Transmission2 pages including this page

TO: Examiner Ron Schwadron
Fax No.: 703-308-4242
Phone No.: 703-308-4680

RE: Corrected Response of 10/23/01
Your Reference: 09/164,223

Our Reference: 210121.465

☐ Urgent ☐ For Review ☐ Please Confirm Receipt ☐ Please Reply ASAP

Comments:

Dear Examiner Schwadron: Per our telephone conversation yesterday, April 8, 2002, attached is the requested corrected page of the Version with Markings to Show Changes Made from our Response of 10/23/01. Please let me know if you require anything further. Thank you.

If you do not receive all pages, please call Judy Davies at (206) 622-4900 or fax our office.

Transmission Information: Date 4-9-02 Time 11:08 By WLC

CONFIDENTIALITY NOTICE: The information contained in this facsimile message is legally privileged and/or confidential information intended only for the use of the addressee named above. If you are not the intended recipient, you are hereby notified that any use, dissemination, distribution, or copying of this facsimile or its content is strictly prohibited. If you have received this facsimile in error, please immediately notify us by telephone and return the original facsimile message to us by mail or destroy it without making a copy. Thank you.

react with WT1-specific antisera and/or T-cell lines or clones is not substantially diminished, wherein the immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2 or 3.

107. (Amended) A pharmaceutical composition comprising a polypeptide an immunogenic portion of native WT1 according to claim 104, wherein the immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2 in combination with a pharmaceutically acceptable carrier or excipient.

108. (Amended) An immunogenic composition comprising a polypeptide an immunogenic portion of native WT1, wherein the immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2 according to claim 104, in combination with a non-specific immune response enhancer.

109. (Amended) A immunogenic composition according to claim 108, wherein the immune response enhancer is an adjuvant.

110. (Amended) A immunogenic composition comprising:

(a) a WT1 polypeptide, wherein the polypeptide comprises consisting of an immunogenic portion of a native WT1 or a variant thereof that differs from the immunogenic portion due to substitutions at between 1 and 3 amino acid positions within the immunogenic portion, in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific T cell lines or clones is not substantially diminished; and

(b) a non-specific immune response enhancer that preferentially enhances a T cell response in a patient;

wherein said WT1 polypeptide immunogenic portion comprises consists of the contiguous amino acids of SEQ ID NO:2 or 3.

111. (Amended) A immunogenic composition according to claim 110, wherein the immune response enhancer is selected from the group consisting of Montanide

*** TX REPORT ***

TRANSMISSION OK

TX/RX NO	0064	
CONNECTION TEL		#64817033084242
CONNECTION ID	TC 1600	
ST. TIME	04/09 11:08	
USAGE T	00'25	
PGS. SENT	2	
RESULT	OK	

SEED

Intellectual Property Law Group PLLC

701 Fifth Avenue, Suite 6300
Seattle WA 98104-7092 USA
Facsimile: (206) 682-6031
Telephone: (206) 622-4900
www.seedlaw.com

Julie A. Urvater, Ph.D.
julieu@seedlaw.com

April 9, 2002

Facsimile Transmission

2 pages including this page

TO: Examiner Ron Schwadron
Fax No.: 703-308-4242
Phone No.: 703-308-4680

RE: Corrected Response of 10/23/01
Your Reference: 09/164,223

Our Reference: 210121.465

☐ Urgent ☐ For Review ☐ Please Confirm Receipt ☐ Please Reply ASAP

Comments:

Dear Examiner Schwadron: Per our telephone conversation yesterday, April 8, 2002, attached is the requested corrected page of the Version with Markings to Show Changes Made from our Response of 10/23/01. Please let me know if you require anything further. Thank you.

If you do not receive all pages, please call Judy Davies at (206) 622-4900 or fax our office.